Download PDF
Thromb Haemost 2003; 89(04): 726-734
DOI: 10.1055/s-0037-1613579
Cellular Proteolysis and Oncology
Schattauer GmbH

Systemic coagulation reactivation in recurrence of colorectal cancer

Lene H. Iversen
1   Department of Clinical Epidemiology, Aarhus University Hospital, Denmark
,
Ole Thorlacius-Ussing
2   Department of Surgical Gastroenterology A, Aalborg Hospital, Denmark
› Author Affiliations
Further Information

Publication History

Received 10 September 2002

Accepted after revision 21 January 2003

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

At time of diagnosis, most cancer patients present with laboratory evidence of systemic coagulation activation. After treatment with curative intent, these hemostatic alterations seemingly disappear as seen in colorectal cancer with regard to prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), and soluble fibrin (SF).

The aim of this study was to investigate whether coagulation activation recurs with cancer recurrence and to study whether preoperative coagulation tests have any prognostic value in colorectal cancer.

Plasma F1+2, TAT, and SF levels were prospectively recorded from 113 patients followed after curative resection of colo-rectal cancer. The patients were seen in clinic after 3, 6, 12, and 18 months, and after 2, 3, 4, and 5 years.

Coagulation reactivation was observed at the time of recurrence, as demonstrated by significantly increased plasma TAT and SF, along with a non-significant increase (P = 0.09) in F1+2.

Preoperative values of F1+2,TAT, and SF did not show association with prognosis.

Keywords

Colorectal neoplasms - prospective studies - prognosis - blood coagulation - recurrence
 

  • References

  • 1 Dano K, Andreasen PA, Grondahl Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
    PubMedGoogle Scholar
  • 2 Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993; 69: 406-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicenter trial with veno-graphic assessment. Br J Surg 1997; 84: 1099-103.
    CrossrefPubMedGoogle Scholar
  • 4 Iversen LH, Thorlacius-Ussing O. Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 2002; 87: 402-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
    CrossrefPubMedGoogle Scholar
  • 6 Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-73.
    CrossrefPubMedGoogle Scholar
  • 7 Rickles FR, Levine M, Edwards RL. Hemo-static alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-48.
    CrossrefPubMedGoogle Scholar
  • 8 Iversen LH, Okholm M, Thorlacius Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease a preliminary study. Thromb Haemost 1996; 76: 523-8.
    PubMedGoogle Scholar
  • 9 Iversen LH. Coagulation and fibrinolysis in patients undergoing surgery for colorectal cancer as assessed by sensitive markers. Ph.D.-thesis. Aalborg. 1997
    PubMedGoogle Scholar
  • 10 Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo. Blood Coagul Fibrinolysis 1993; 4: 97-102.
    CrossrefPubMedGoogle Scholar
  • 13 Bland JM, Altman DG. The use of transformation when comparing two means. BMJ 1996; 312: 1153.
    CrossrefPubMedGoogle Scholar
  • 14 Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-84.
    CrossrefPubMedGoogle Scholar
  • 15 Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215-V224.
    CrossrefPubMedGoogle Scholar
  • 16 Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol 2001; 106: 33-42.
    CrossrefPubMedGoogle Scholar
  • 17 Lip GY, Chin BS, Blann AD. Cancer and the pro-thrombotic state. Lancet Oncol 2002; 3: 27-34.
    CrossrefPubMedGoogle Scholar
  • 18 Lindahl AK, Odegaard OR, Sandset PM, Harbitz TB. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Cancer 1992; 70: 2067-72.
    CrossrefPubMedGoogle Scholar
  • 19 Levi M. Cancer and DIC. Haemostasis 2001; 31 01 Suppl 47-8.
    PubMedGoogle Scholar
  • 20 Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86: 828-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Wojtukiewicz MZ, Zacharski LR, Moritz TE, Hur K, Edwards RL, Rickles FR. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinolysis 1992; 3: 429-37.
    CrossrefPubMedGoogle Scholar
  • 22 Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001; 17: 667-73.
    CrossrefPubMedGoogle Scholar
  • 23 Seitz R, Rappe N, Kraus M, Immel A, Wolf M, Maasberg M, Egbring R, Pfab R, Havemann K. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 1993; 4: 249-54.
    CrossrefPubMedGoogle Scholar
  • 24 Gadducci A, Baicchi U, Marrai R, Facchini V, Del Bravo B, Fosella PV, Fioretti P. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. Gynecol Oncol 1993; 49: 354-8.
    CrossrefPubMedGoogle Scholar
  • 25 Gadducci A, Baicchi U, Marrai R, Del Bravo B, Fosella PV, Facchini V. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994; 53: 352-6.
    CrossrefPubMedGoogle Scholar
  • 26 Iversen LH, Thorlacius Ussing O. Short-time stability of markers of coagulation and fibrinolysis in frozen plasma. Thromb Res 1996; 81: 253-61.
    CrossrefPubMedGoogle Scholar
  • 27 Pokorny RM, Hunt L, Galandiuk S. What’s new with tumor markers for colorectal cancer?. Dig Surg 2000; 17: 209-15.
    CrossrefPubMedGoogle Scholar
  • 28 Mannucci PM. Mechanisms, markers and management of coagulation activation. Br Med Bull 1994; 50: 851-70.
    CrossrefPubMedGoogle Scholar
  • 29 Chang HR, Bland KI, Zinner M, Schwartz SI, Ellis H. Editors Maingot’s Abdominal Operations. 10 ed. Connecticut: Appleton & Lange. Tumors of the colon 1997; 421: 281-308.
    PubMedGoogle Scholar